Xeroderma Pigmentosum is a genetic skin condition in which the skin and tissue covering the eye is very sensitive to ultraviolet light. When the sun hits this skin, it damages the DNA and cannot repair itself. Because the skin cannot repair, children usually develop skin cancer by the age of 5. Symptoms of Xeroderma Pigmentosum include sunburns that don’t heal, blistering, crusting, oozing after minimal sun exposure, and patches of discolored skin. Most people with Xeroderma Pigmentosum will die of skin cancer in early adulthood, but this can be delayed with the use of high SPF sunscreen and dark glasses.
Xeroderma Pigmentosum Bioinformatics Tool
Laverne is a handy bioinformatics tool to help facilitate scientific exploration of related genes, diseases and pathways based on co-citations. Explore more on Xeroderma Pigmentosum below!
For more information on how to use Laverne, please read the How to Guide.
We have 1228 products for the study of Xeroderma Pigmentosum that can be applied to Western Blot, Flow Cytometry, Chromatin Immunoprecipitation, Immunohistochemistry, Immunocytochemistry/Immunofluorescence, Chromatin Immunoprecipitation (ChIP) from our catalog of antibodies and ELISA kits.
Xeroderma Pigmentosum is also known as xeroderma pigmentosum, desanctis-cacchione syndrome, xerodermic idiocy, des syndrome, xeroderma.
PRODUCT AVAILABILITY: Update Regarding the Evolving COVID-19 Situation
Bio-Techne appreciates the critical role that you and our products and services play in research efforts to further scientific innovation and discovery. We are continually assessing our manufacturing and supplier capabilities during the COVID-19 situation and are implementing precautionary measures to ensure uninterrupted supply of products and services. Currently, and as we abide by local shelter in place orders across the world, we are fully operational and do not anticipate any material supply disruptions across our Bio-Techne brands and product lines. As the situation evolves, our goal is to utilize preventive measures to reduce the threat that COVID-19 poses to our ability to meet the needs of our customers globally.